Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1
Summary
USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.
What changed
USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating diseases including atherosclerosis. The application claims compositions including PIP2 affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce unwanted cholesterol and atherosclerosis.
For pharmaceutical and biotechnology companies developing cardiovascular or lipid metabolism therapies, this patent application establishes a filing date and potential future IP rights in the cholesterol/atherosclerosis treatment space. Competitors developing similar therapies should monitor application status, evaluate freedom-to-operate, and consider filing protests or submitting prior art during examination.
What to do next
- Monitor for patent grant status
- Evaluate freedom-to-operate if developing related cardiovascular or lipid metabolism therapies
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR MODULATING CHOLESTEROL EFFLUX
Application US20260097053A1 Kind: A1 Apr 09, 2026
Inventors
KAILASH GULSHAN
Abstract
Compositions and methods for diagnosing, treating, preventing, inhibiting, or ameliorating the symptoms of a disease or disorder that is modulated or otherwise affected by ABCA1 levels and cholesterol efflux or in which ABCA1 levels and cholesterol efflux is implicated are disclosed herein. PIP2 is shown to affect ABCA1 levels and promote RCT leading to reductions in unwanted cholesterol levels and atherosclerosis.
CPC Classifications
A61K 31/683 A61K 38/45 A61K 48/005 C12N 15/86 C12N 2750/14143 C12Y 207/01068
Filing Date
2025-04-21
Application No.
19184214
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.